SCHEMBL10127092

SCHEMBL10127092

CSc1nc(Cl)c(C(N)=O)c(Nc2ccc3c(c2)C(=O)NCC3)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 5/20 0.43
▸ PARP10 Q53GL7 5/20 0.43
▸ F7 P08709 1/20 0.43
▸ F3 P13726 1/20 0.43
▸ WEE1 P30291 1/20 0.40
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA7 P43166 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.35
▸ CA13 Q8N1Q1 1/20 0.35
▸ CCNA2 P20248 2/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CDK6 Q00534 1/20 0.35
▸ MET P08581 1/20 0.34
▸ ALK Q9UM73 1/20 0.34
▸ CAMK2D Q13557 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17340333 0.82 CA1 (0.38) CA1CA2CA7CA13CCNA2
SCHEMBL10127120 0.82 PARP1 (0.39) PARP1PARP10F7F3WEE1
SCHEMBL17340295 0.76 PARP1 (0.38) PARP1PARP10F7F3WEE1
SCHEMBL10127227 0.75 CA1 (0.40) CA1CA2CA7CA13MEN1
SCHEMBL10127090 0.75 CA1 (0.48) CA1CA2CA7MAPK1CA13
SCHEMBL10126491 0.74 CA1 (0.41) CA1CA2CA7MAPK1CA13
SCHEMBL17069444 0.73 LMNA (0.47) PPARG
SCHEMBL10127040 0.73 TP53 (0.46) CDK2CDK4ALKPPARG
SCHEMBL10156670 0.72 PPARG (0.41) CA1CA2CA7CA13MEN1
SCHEMBL10126533 0.72 CA1 (0.44) CA1CA2CA7MAPK1CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 — — US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 — — US disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 — — EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 — — US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 — — US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 — — US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 — — US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 — — US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 — — US disclosed
WO-2010128659-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2010-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 PARP1 1748/4885PARP10 667/4885F7 4099/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 PARP1 1748/4885PARP10 667/4885F7 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback